Bevacizumab plus erlotinib for RMC скачать в хорошем качестве

Bevacizumab plus erlotinib for RMC

Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the efficacy of bevacizumab plus erlotinib (B+E) in patients with renal medullary carcinoma (RMC). Comprehensive molecular profiling of RMC tissue found a decreased expression in genes related to the tricarboxylic acid (TCA) cycle and oxidative phosphorylation, as well as an increase in the expression of genes involved in fatty acid synthesis, demonstrating a reliance of aerobic glycolysis. B+E has previously shown efficacy in tumors which rely on aerobic glycolysis. An analysis of ten patients with RMC who were treated with B+E found that a partial response was achieved in 20% of patients and stable disease was achieved in 60% of patients with a median progression-free survival (PFS) of 3.5 months. The median overall survival (OS) from B+E initiation was 7.3 months. This interview took place during the 2021 Genitourinary Cancers Symposium.